---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-001820"
form_type: "8-K"
ticker: "IDXX"
cik: "0000874716"
company_name: "IDEXX LABORATORIES INC /DE"
filed_at: "2023-02-06T23:59:59+00:00"
generated_at: "2026-06-20T00:40:34.405493+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# IDEXX Q4 revenue +7% organic; EPS $2.05; FY23 guidance rev $3.59B-$3.69B, EPS $9.27-$9.75

## Summary
- Q4 revenue $829M (+3% reported, +7% organic); EPS $2.05 (+8% reported, +14% comparable).
- FY2022 revenue $3,367M (+5% reported, +7% organic); EPS $8.03 (-7% reported, -1% comparable, including discrete R&D headwind).
- CAG Diagnostics recurring revenue grew 4% reported, 8% organic in Q4; global premium instrument installed base up 13% YoY.
- FY2023 guidance: revenue $3.59B-$3.69B (6.5%-9.5% reported growth); EPS $9.27-$9.75 (16%-21% reported growth).
- Q4 operating margin 27.3% (+240bps reported); 2023 operating margin target 29.0%-29.6%.

## SEC filing metadata
- accession: 0000950170-23-001820
- form_type: 8-K
- ticker: IDXX
- cik: 0000874716
- company_name: IDEXX LABORATORIES INC /DE
- filed_at: 2023-02-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874716/000095017023001820/0000950170-23-001820-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874716/000095017023001820/idxx-20230206.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-001820
- JSON: https://secwatch.observer/filing/0000950170-23-001820.json
- Plain text: https://secwatch.observer/filing/0000950170-23-001820.txt

## Key facts
- Earnings Releases
  IDEXX LABORATORIES INC /DE updated its the quarter and year ended December 31, 2022 guidance (initiated).
  - Period: the quarter and year ended December 31, 2022
  - Guidance: initiated
  - Result: reported results
  source text: IDEXX Laboratories, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/874716/000095017023001820/0000950170-23-001820-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.